. There were no differences
in the rates of volume depletion AEs between treatment
groups, and no patients discontinued treatment as a result.
At least one elevated liver test during the 4 years occurred
in 3.8% of dapagliflozin patients and in 4.5% of glipizide
patients (Tables S6 and S7)